Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος [ Τύπος(Asc)] Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Tziomalos, K., Kakafika A. I., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  The role of statins for the primary and secondary prevention of coronary heart disease in women.. Curr Pharm Des. 15(10), 1054-62.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., Kakafika A. I., Tziomalos K., Liberopoulos E. N., et al. (2007).  The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. Expert Opin Ther Targets. 11(2), 191-205.
Kakafika, A. I., Mikhailidis D. P., Karagiannis A., & Athyros V. G. (2007).  The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.. J Clin Pharmacol. 47(5), 642-52.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2010).  The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification.. Curr Opin Cardiol. 25(4), 394-8.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'.. Clin Cardiol. 35(5), 315; author reply 316-7.
Kargiotis, K., Athyros V. G., Giouleme O., Katsiki N., Katsiki E., Anagnostis P., et al. (2015).  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.. World J Gastroenterol. 21(25), 7860-8.
Pagourelias, E. D., Gossios T. D., Tziomalos K., Karagiannis A., Geleris P., & Athyros V. G. (2011).  Residual cardiac risk reduction beyond lipid lowering.. Hellenic J Cardiol. 52(3), 197-203.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
Athyros, V. G., Karagiannis A., Katsiki N., & Mikhailidis D. P. (2012).  Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.. Am J Cardiol. 110(5), 763.
Reklou, A., Doumas M., Imprialos K., Stavropoulos K., Patoulias D., & Athyros V. G. (2018).  Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovasc Med J. 12, 29-40.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Reaching hypertriglyceridemia goals.. Curr Med Res Opin. 30(3), 391-3.
Kakafika, A. I., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother. 9(9), 1437-40.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. Curr Pharm Des. 16(34), 3939-847.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opin Investig Drugs. 17(12), 1777-9.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2014).  Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.. Expert Rev Cardiovasc Ther. 12(3), 295-6.
Imprialos, K. P., Stavropoulos K., Doumas M., Skalkou A., Zografou I., & Athyros V. G. (2018).  The potential role of statins in treating liver disease.. Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., & Harsoulis F. (2007).  Pheochromocytoma: an update on genetics and management.. Endocr Relat Cancer. 14(4), 935-56.
Filippatos, T. D., Athyros V. G., & Elisaf M. S. (2014).  The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].. Expert Opin Drug Metab Toxicol. 10(6), 787-812.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Peripheral artery disease in patients with type 2 diabetes.. J Diabetes Complications. 28(6), 912.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές